Baseline characteristics of the study population (N = 3609)
| . | CLL patients (%) . |
|---|---|
| Patient-related factors | |
| Sex | |
| Male | 2170 (60.1) |
| Female | 1439 (39.9) |
| Age groups, y | |
| ≤60 | 685 (19.0) |
| >60 and ≤70 | 1194 (33.1) |
| >70 and ≤80 | 1114 (30.1) |
| >80 | 619 (17.2) |
| WHO-PF | |
| 0-1 | 3393 (94.0) |
| >1 | 199 (5.5) |
| Missing | 17 (0.5) |
| Previous VTE | |
| No | 3486 (96.6) |
| Yes | 123 (3.4) |
| Cancer before CLL | |
| No | 3107 (86.1) |
| Yes | 502 (13.9) |
| Second primary cancer after CLL | |
| No | 3148 (87.2) |
| Yes | 461 (12.8) |
| Anticoagulation medication during follow-up | |
| No | 3382 (93.7) |
| Yes | 227 (6.3) |
| CLL-specific markers | |
| CLL risk group | |
| Low | 2279 (63.1) |
| High | 788 (21.8) |
| Not assessed | 529 (14.7) |
| Missing | 13 (0.4) |
| Binet stage | |
| A | 2866 (79.4) |
| B | 536 (14.9) |
| C | 207 (5.7) |
| IgHV mutational status | |
| Mutated | 1902 (52.7) |
| Unmutated | 901 (25.0) |
| Not assessed | 806 (22.3) |
| FISH | |
| Normal | 932 (25.8) |
| Abnormal | 2164 (60.0) |
| Not assessed | 513 (14.2) |
| Del11q and/or del17p | 400 (11.1) |
| Del13 | 1705 (47.2) |
| Trisomy 12 | 419 (11.6) |
| β2-microglobulin, mg/L | |
| <4 | 2325 (64.4) |
| ≥4 | 365 (10.1) |
| Not assessed | 919 (25.4) |
| CLL treatment* | |
| Yes | 560 (15.5) |
| No | 3049 (84.5) |
| . | CLL patients (%) . |
|---|---|
| Patient-related factors | |
| Sex | |
| Male | 2170 (60.1) |
| Female | 1439 (39.9) |
| Age groups, y | |
| ≤60 | 685 (19.0) |
| >60 and ≤70 | 1194 (33.1) |
| >70 and ≤80 | 1114 (30.1) |
| >80 | 619 (17.2) |
| WHO-PF | |
| 0-1 | 3393 (94.0) |
| >1 | 199 (5.5) |
| Missing | 17 (0.5) |
| Previous VTE | |
| No | 3486 (96.6) |
| Yes | 123 (3.4) |
| Cancer before CLL | |
| No | 3107 (86.1) |
| Yes | 502 (13.9) |
| Second primary cancer after CLL | |
| No | 3148 (87.2) |
| Yes | 461 (12.8) |
| Anticoagulation medication during follow-up | |
| No | 3382 (93.7) |
| Yes | 227 (6.3) |
| CLL-specific markers | |
| CLL risk group | |
| Low | 2279 (63.1) |
| High | 788 (21.8) |
| Not assessed | 529 (14.7) |
| Missing | 13 (0.4) |
| Binet stage | |
| A | 2866 (79.4) |
| B | 536 (14.9) |
| C | 207 (5.7) |
| IgHV mutational status | |
| Mutated | 1902 (52.7) |
| Unmutated | 901 (25.0) |
| Not assessed | 806 (22.3) |
| FISH | |
| Normal | 932 (25.8) |
| Abnormal | 2164 (60.0) |
| Not assessed | 513 (14.2) |
| Del11q and/or del17p | 400 (11.1) |
| Del13 | 1705 (47.2) |
| Trisomy 12 | 419 (11.6) |
| β2-microglobulin, mg/L | |
| <4 | 2325 (64.4) |
| ≥4 | 365 (10.1) |
| Not assessed | 919 (25.4) |
| CLL treatment* | |
| Yes | 560 (15.5) |
| No | 3049 (84.5) |
FISH, fluorescence in situ hybridization.
Analysis regarding CLL treatment is restricted to the first year after the CLL diagnosis, and 34 VTEs occurred in this period.